Grifols, S.A. American Depositary Receipt (GRFS)
Summary
Grifols Q2 Earnings Call Highlights
Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy.
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.
Grifols, S.A. American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 653 | $5,618.41 | $5,139.11 | -$479.3 | -8.53% |
| NA Nizar Araji National Bank Of Canada /FI/ | 8,102 | $59,927.26 | $64,491.92 | $4,564.66 | 7.62% |
 Charles Brandes Brandes Investment Partners | 37.82M | $342.5M | $294.21M | -$48.29M | -14.1% |
 Anthony Scaramucci SkyBridge Capital II LLC | 2.94M | $25.31M | $22.84M | -$2.47M | -9.75% |
 Point72 Asset Management LP Point72 Asset Management LP | 25,794 | $241,173.89 | $200,677.32 | -$40,496.57 | -16.79% |
Grifols, S.A. American Depositary Receipt (GRFS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Grifols, S.A. American Depositary Receipt ever had a stock split?
Grifols, S.A. American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Jose Ignacio Abia Buenache CEO | NASDAQ (NGS) Exchange | 398438408 CUSIP |
| ES Country | 25,258 Employees | 2 Jul 2026 Last Dividend | 11 Dec 2012 Last Split | - IPO Date |
Overview
Grifols, S.A., headquartered in Barcelona, Spain, is a pioneering company in the plasma therapeutic industry with a wide-ranging international presence, including operations in Spain, the United States, Canada, and other countries worldwide. Founded in 1909, the company has established itself as a major player in the healthcare sector, focusing on the innovation, development, and marketing of plasma-derived medicines to treat various diseases. Grifols engages in comprehensive activities spanning the collection and processing of plasma, research and development of new therapeutic applications, manufacturing, and the marketing of diagnostics, pharmaceutical products, and plasma-derived products. It also extends its services to include diagnostic testing equipment and reagents, with a strong commitment to advancing treatment in immunology, hematology, and other medical fields through collaborative agreements and extensive research initiatives.
Products and Services
- Immunoglobulin: Used for treating primary immunodeficiencies, this product leverages antibodies from plasma to enhance the body's immune response.
- Albumin: This plasma-derived product is essential for treating conditions that cause protein loss or require volume restoration, such as liver cirrhosis and severe burns.
- Alpha-1 Proteinase Inhibitor: A treatment for Alpha-1 Antitrypsin Deficiency, a genetic disorder that can affect the lungs and liver.
- Clotting Factors (FactorVIII/von Willebrand factor and Factor IX): Essential for the treatment of bleeding disorders like hemophilia A, von Willebrand's disease, and hemophilia B.
- Antithrombin III: Targeted towards individuals with hereditary antithrombin deficiency to prevent excessive blood clotting.
- Fostamatinib: A spleen tyrosine kinase inhibitor used in the treatment of various conditions.
- Fibrinogen and Thrombin Combination: Acts as a biological sealant to control bleeding during surgical procedures.
- Plasma Exchange with Albumin for Alzheimer's Disease: An innovative treatment approach utilizing plasma exchange to address Alzheimer’s disease.
- Diagnostic Testing Equipment and Reagents: Offers a range of equipment and reagents for diagnostic testing, supporting medical laboratories and healthcare facilities.
- Pharmaceutical Products for Hospital Pharmacies: Supplies a variety of pharmaceutical products tailored for use in hospital settings.
- Yimmugo PID and ITP: Specialized drugs in the fields of immunology and hematology, addressing primary immunodeficiencies and immune thrombocytopenia, respectively.
- Development Stage Products: Includes products like Xembify (for immunodeficiencies) in various formulations, Prolastin (for Alpha-1 Antitrypsin Deficiency), and innovative treatments such as Fibrinogen, Trimodulin, and AKST4290 in different stages of clinical development.
- Collaborative Agreements: Grifols has entered into significant partnerships, including with Canadian Blood Services, GIANT, and GigaGen, to expand its research, development, and distribution of plasma-derived and recombinant polyclonal immunoglobulin therapies.
